Authors: Ruiz M Parsons C Cole J
Address: Section of Infectious Diseases and Geriatric Medicine, Department of Medicine, Louisiana State University Health Sciences Center in New Orleans, New Orleans, LA.
Journal:

Publication:

abstract

Introduction: Although the incidence and prevalence of AIDS-defining malignancies has decreased in the era of highly active antiretroviral therapy (HAART), the incidence and prevalence of Hodgkin's Lymphoma (HL) in the HIV-Infected population continues to rise. Compared with the general population, HIV-infected Patients exhibit a 5-10-fold increased risk for developing HL. METHODS: A retrospective review of charts and electronic records from 2000-2010 at the HIV outpatient clinic (HOP)-Louisiana State University in New Orleans was conducted, and pathologically confirmed cases of HIV-HL were identified within this cohort. RESULTS: We found a prevalence of 6.3 cases per 1,000 patients per year of HIV-HL over a period of 10 years in our HIV outpatient clinic. The mean absolute CD4 count before treatment was 284 cells/mm(3) and after treatment was 194 cells/mm(3). The average time from the diagnosis of HIV infection to the diagnosis of HIV-HL was 7.6 years. The most common histopathologic type was mixed cellularity followed by lymphocytic predominance. The majority of patients had 6 cycles delivered. In terms of HL staging 87% presented with advanced stages (III B or IV). To the best of our knowledge 5 out of the 14 patients remain alive. Conclusions: Patients in our cohort were older than most patients identified in other cohorts. All of our patients had coexisting chronic illnesses Associated with inflammation, as well as detectable HIV viral loads and CD4 count > 200, suggesting a role for both HIV- and non-HIV-associated inflammation in HIV-HL pathogenesis in this population. The role of HIV virus and other oncogenic viruses (EBV, HPV, and others) in the pathogenesis of Hodgkin's lymphoma in this group of patients needs to be elucidated.

Related Articles
Final Report on Carcinogens Background Document for Formaldehyde.
Rep Carcinog Backgr Doc. 2010
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program. Rep Carcinog Backgr Doc. 2010 Jan; (10-5981):i-512.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008
Final Report on Carcinogens Background Document for Styrene.
National Toxicology Program. Rep Carcinog Backgr Doc. 2008 Sep; (8-5978):i-398.
[Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Med Mal Infect. 2006
[Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C, Cormerais L, Gourdon F, Peigue-Lafeuille H, Travade P, et al. Med Mal Infect. 2006 Mar; 36(3):157-62. Epub 2006 Feb 28.
Review Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection.
Expert Rev Anticancer Ther. 2004
Review Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection.
Hartmann P, Rehwald U, Salzberger B, Franzen C, Diehl V. Expert Rev Anticancer Ther. 2004 Jun; 4(3):401-10.
Review HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
Oncol Rep. 2007
Review HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
Barbaro G, Barbarini G. Oncol Rep. 2007 May; 17(5):1121-6.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster